Takeda Drops Orteronel Prostate Cancer Drug After Phase III Trials
This article was originally published in PharmAsia News
Takeda Pharmaceutical said it is dropping its TAK-700 (orteronel) drug for treating prostate cancer because it proved no better than alternatives in two Phase III trials in the U.S. and Europe.
You may also be interested in...
The FDA has revealed details of its recent warning letter to Shilpa, which cites the company’s failure to adequately investigate out-of-specification results and complaints as well as to follow written procedures for complaint handling.
Diabetes-related foot amputations are on the rise in the UK. Stada through its UK subsidiary Thornton & Ross is partnering with Diabetes UK to promote foot health and the benefits of using its leading OTC foot-care brand, Flexitol.
The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.